Urologix Inc., a leading provider of in-office BPH therapy reached an important milestone in its licensing agreement with Medtronic for the Prostiva RF Therapy System. In accordance with the terms of the agreement, Urologix has become the licensed manufacturer for the Prostiva RF Therapy System, taking manufacturing and regulatory responsibility for the medical device product line.
This milestone represents an important step in the integration of the Prostiva product line into the broader Urologix organization, allowing the company to work directly with our manufacturing partners to ensure continued focus on both quality and efficiency going forward. In addition, achieving this milestone enables the Company to market and sell all Prostiva RF Therapy products distributed throughout the United States under the Urologix brand name.
"The Urologix team is well prepared and excited to take over the responsibility for all aspects of the Prostiva system," states Greg Fluet, CEO. "Our team can now present the two leading in-office BPH technologies under one Urologix brand. These Urologix products enable our urologist customers to optimize care for their patients who are frustrated with the lack of value provided by drug therapies and are unwilling to undergo more invasive surgical procedures."